Zentalis Pharmaceuticals Inc (ZNTL): A Technical Analysis

ZNTL has 36-month beta value of 1.72. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for ZNTL is 63.83M, and currently, short sellers hold a 26.22% ratio of that float. The average trading volume of ZNTL on April 03, 2024 was 820.86K shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

ZNTL) stock’s latest price update

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)’s stock price has dropped by -10.54 in relation to previous closing price of 16.13. Nevertheless, the company has seen a gain of 6.26% in its stock price over the last five trading days. Zacks Investment Research reported 2024-02-28 that The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ZNTL’s Market Performance

ZNTL’s stock has risen by 6.26% in the past week, with a monthly drop of -5.56% and a quarterly drop of -4.75%. The volatility ratio for the week is 8.04% while the volatility levels for the last 30 days are 7.06% for Zentalis Pharmaceuticals Inc The simple moving average for the past 20 days is -0.38% for ZNTL’s stock, with a -22.25% simple moving average for the past 200 days.

Analysts’ Opinion of ZNTL

Many brokerage firms have already submitted their reports for ZNTL stocks, with Wedbush repeating the rating for ZNTL by listing it as a “Neutral.” The predicted price for ZNTL in the upcoming period, according to Wedbush is $12 based on the research report published on November 08, 2023 of the previous year 2023.

Leerink Partners, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $15. The rating they have provided for ZNTL stocks is “Market Perform” according to the report published on November 07th, 2023.

ZNTL Trading at 6.74% from the 50-Day Moving Average

After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.13% of loss for the given period.

Volatility was left at 7.06%, however, over the last 30 days, the volatility rate increased by 8.04%, as shares sank -0.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.95% upper at present.

During the last 5 trading sessions, ZNTL rose by +6.26%, which changed the moving average for the period of 200-days by -41.41% in comparison to the 20-day moving average, which settled at $14.48. In addition, Zentalis Pharmaceuticals Inc saw -4.75% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ZNTL starting from Epperly Melissa B, who sale 2,573 shares at the price of $11.44 back on Feb 12 ’24. After this action, Epperly Melissa B, now owns 451,449 shares of Zentalis Pharmaceuticals Inc, valued at $29,435 using the latest closing price.

Gallagher Cam, the President of Zentalis Pharmaceuticals Inc, sale 1,173 shares at $11.44 during a trade that took place back on Feb 12 ’24, which means that Gallagher Cam is holding 643,277 shares at $13,419 based on the most recent closing price.

Stock Fundamentals for ZNTL

The total capital return value is set at -0.61. Equity return is now at value -67.09, with -52.39 for asset returns.

Based on Zentalis Pharmaceuticals Inc (ZNTL), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -4.54. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 50.33.

Currently, EBITDA for the company is -252.55 million with net debt to EBITDA at -0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.16.

Conclusion

To put it simply, Zentalis Pharmaceuticals Inc (ZNTL) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts